

**2**  
**Name of Journal: *World Journal of Gastroenterology***  
**Manuscript NO: 52092**  
**Manuscript Type: ORIGINAL ARTICLE**

**Basic Study**

**LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway**

Chen XY *et al.* LB100 ameliorates nonalcoholic fatty liver disease

**Abstract**

**BACKGROUND**

It is well known that nonalcoholic fatty liver disease (NAFLD) is associated

**Match Overview**

<b>1</b>	<b>Internet</b> 49 words crawled on 03-Oct-2019 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	1%
<b>2</b>	<b>Internet</b> 31 words crawled on 01-Nov-2019 <a href="http://f6publishing.blob.core.windows.net">f6publishing.blob.core.windows.net</a>	1%
<b>3</b>	<b>Crossref</b> 27 words Matilda Lee, Jayshree L. Hirpara, Jie-Qing Eu, Gautam Sethi, Lingzhi Wang, Boon-Cher Goh, Andrea L. Wong. "Target..."	1%
<b>4</b>	<b>Crossref</b> 24 words Bing Zhou, Dan-li Zhou, Xiao-hong Wei, Rong-yu Zhong, Jie Xu, Liao Sun. "Astragaloside IV attenuates free fatty acid-i..."	1%
<b>5</b>	<b>Internet</b> 20 words <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%
<b>6</b>	<b>Internet</b> 15 words crawled on 29-Aug-2017 <a href="http://hal.archives-ouvertes.fr">hal.archives-ouvertes.fr</a>	<1%
<b>7</b>	<b>Crossref</b> 14 words Bánréti, Ágnes, Tamás Lukácsovich, György Csikós, Miklós Erdélyi, and Miklós Sass. "PP2A regulates autophagy in two"	<1%



27,100 Results Any time ▾

**[PDF] Protective Effects of Licochalcone A Ameliorates Obesity ...**<https://www.mdpi.com/2073-4409/8/5/447/pdf>

Protective Effects of Licochalcone A **Ameliorates** Obesity and **Non-Alcoholic Fatty Liver Disease Via** Promotion of the **Sirt-1/AMPK Pathway** in Mice Fed a High-Fat Diet Chian-Jiun Liou 1,2,y, Yau-Ker Lee 3,y, Nai-Chun Ting 4, Ya-Ling Chen 5,6, Szu-Chuan Shen 7, ...

**Cited by:** 3 **Author:** Chian-Jiun Liou, Yau-Ker Lee, Nai-Chun ...**Publish Year:** 2019**(PDF) Protective Effects of Licochalcone A Ameliorates ...**[https://www.researchgate.net/publication/333050387\\_Protective\\_Effects\\_of\\_Licochalcone...](https://www.researchgate.net/publication/333050387_Protective_Effects_of_Licochalcone...)

Protective Effects of Licochalcone A **Ameliorates** Obesity and **Non-Alcoholic Fatty Liver Disease Via** Promotion of the **Sirt-1/AMPK Pathway** in Mice Fed a High-Fat Diet Article (PDF Available) · May ...

**Spermidine ameliorates non-alcoholic fatty liver disease ...**<https://www.sciencedirect.com/science/article/pii/S0006291X18320035>

Oct 20, 2018 - **AMPK** is a central metabolic regulator and may serve as the therapeutic target of treating obesity, **non-alcoholic fatty liver disease** and type 2 diabetes . Thus, to explore whether spermidine activates **AMPK** and regulates lipid metabolism, we detected the level of **AMPK** phosphorylation and its downstream gene expression in vivo and in vitro .

**Cited by:** 3 **Author:** Mingyue Gao, Wei Zhao, Chunmei Li, Xia...**Publish Year:** 2018**Celastrol ameliorates liver metabolic damage caused by a ...**<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220393>

Nov 17, 2016 - Celastrol was recently identified as a potential novel treatment for obesity. However, the effect of Celastrol on **nonalcoholic fatty liver disease** (NAFLD) remains elusive. The aim of this study is to evaluate the role of Celastrol in NAFLD. Functional studies were performed using wild-type C57BL/6J ...

**Cited by:** 21 **Author:** Yinliang Zhang, Chao Geng, Xiaoyan Liu,...**Publish Year:** 2017**Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic ...**<https://www.sciencedirect.com/science/article/pii/S2213231719308079>



国内版 国际版

LB100 ameliorates nonalcoholic fatty liver disease via the AMF



Chat with Bing

Sign in



All

Images

Videos

开启取词

Add Bing Firefox extension >

15,700 Results

Any time ▾

### [PDF] Protective Effects of Licochalcone A Ameliorates Obesity ...

<https://www.mdpi.com/2073-4409/8/5/447/pdf>

Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet Chian-Jiun Liou 1,2,y, Yau-Ker Lee 3,y, Nai-Chun Ting 4, Ya-Ling Chen 5,6, Szu-Chuan Shen 7, ...

Cited by: 4 Author: Chian-Jiun Liou, Yau-Ker Lee, Nai-Chun T...

Publish Year: 2019

### Protective Effects of Licochalcone A Ameliorates Obesity ...

<https://www.ncbi.nlm.nih.gov/pubmed/31083505>

May 11, 2019 - 1. Cells. 2019 May 11;8(5). pii: E447. doi: 10.3390/cells8050447. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.

Cited by: 4 Author: Chian-Jiun Liou, Yau-Ker Lee, Nai-Chun T...

Publish Year: 2019

### Celastrol ameliorates liver metabolic damage caused by a ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220393>

Nov 17, 2016 - Celastrol was recently identified as a potential novel treatment for obesity. However, the effect of Celastrol on nonalcoholic fatty liver disease (NAFLD) remains elusive. The aim of this study is to evaluate the role of Celastrol in NAFLD. Functional studies were performed using wild-type C57BL/6J ...

Cited by: 22 Author: Yinliang Zhang, Chao Geng, Xiaoyan Liu, ...

Publish Year: 2017

### Dioscin alleviates non-alcoholic fatty liver disease ...

<https://www.sciencedirect.com/science/article/pii/S1043661818303414>

Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway. Based on our data, dioscin exhibited a significant role in improving hepatic lipid metabolism, and decreased triacylglycerol accumulation via activation of SIRT1/AMPK signaling pathway.

Cited by: 18 Author: Hong Yao, Xufeng Tao, Lina Xu, Yan Qi, Li...

Publish Year: 2018



国内版

国际版

LB100 ameliorates nonalcoholic fatty liver disease via the AM



All

Images

Videos

关闭取词

15,900 Results

Any time ▾

### Celastrol ameliorates liver metabolic damage caused by a ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220393>

Nov 17, 2016 · Celastrol was recently identified as a potential novel treatment for obesity. However, the effect of Celastrol on **nonalcoholic fatty liver disease** (NAFLD) remains elusive. The aim of this study is to evaluate the role of Celastrol in NAFLD. Functional studies were performed using wild-type C57BL/6J ...

Cited by: 22

Author: Yinliang Zhang, Chao Geng, Xiaoyan Liu, M...

Publish Year: 2017

### Protective Effects of Licochalcone A Ameliorates Obesity ...

<https://www.ncbi.nlm.nih.gov/pubmed/31083505>

May 11, 2019 · 1. Cells. 2019 May 11;8(5). pii: E447. doi: 10.3390/cells8050447. Protective Effects of Licochalcone A **Ameliorates** Obesity and **Non-Alcoholic Fatty Liver Disease** Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.

Cited by: 4

Author: Chian-Jiun Liou, Yau-Ker Lee, Nai-Chun Tin...

Publish Year: 2019

### Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic ...

<https://www.ncbi.nlm.nih.gov/pubmed/30868489>

Berberine **Ameliorates** High-Fat Diet-Induced **Non-Alcoholic Fatty Liver Disease** in Rats via Activation of SIRT3/AMPK/ACC Pathway. ... our data suggest that the mechanism by which BBR **ameliorates** HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.

### Pinolenic acid ameliorates oleic acid-induced lipogenesis ...

<https://www.sciencedirect.com/science/article/pii/S0014299919305709>

Oct 15, 2019 · Pinolenic acid **ameliorates** oleic acid-induced lipogenesis and oxidative stress via **AMPK/SIRT1** signaling pathway in ... et al. Tetrahydrocurcumin **ameliorates** free fatty acid-induced hepatic steatosis and improves insulin ... L. Xu, et al. Dioscin alleviates **non-alcoholic fatty liver disease** through adjusting lipid metabolism via SIRT1 ...

Cited by: 3

Author: Jing Zhang, Sun-dong Zhang, Peng Wang, ...

Publish Year: 2019

### Pinolenic acid ameliorates oleic acid-induced lipogenesis ...

<https://www.ncbi.nlm.nih.gov/pubmed/31430456>

Oct 15, 2019 · Pinolenic acid **ameliorates** oleic acid-induced lipogenesis and oxidative stress via **AMPK/SIRT1** signaling pathway in HepG2 cells. ... (OA)-induced **non-alcoholic fatty liver disease** (NAFLD)